This technology is a method of reprogramming cellular metabolism to treat neurodegenerative disorders by downregulating catabolism and upregulating anabolism in cells.
There is a desperate need for safe and effective treatment methods of neurodegenerative disorders. Some current treatment methods address the dysregulation of cellular metabolism and focus on using metabolic processes to indirectly clear neurotoxic proteins. Although this type of therapy was effective in animal models, the indirect clearance of toxic proteins leads to many unexpected side effects and can even result in death when applied in humans. As such, there is a need for safe, effective therapies for neurodegenerative diseases that directly intervene with specific cell metabolic pathways.
This technology is a method for reprogramming cellular metabolism to slow or halt neurodegenerative disease progression. This technology utilizes specific glycolytic pathways, small-molecule antagonists, and gene editing approaches to upregulate targeted anabolic processes in cells. This specific reprogramming of cells to a heightened anabolic state enables for the further development of safe, effective therapies for neurodegenerative disorders.
This technology has been validated in mouse models.
IR CU17362
Licensing Contact: Kristin Neuman
